Coronavirus News Roundup: Pfizer Announces 90% Efficacy Rate for Vaccine, FDA Grants EUA to Bamlanivimab

The number of coronavirus disease 2019 (COVID-19) cases in the United States are rapidly increasing, with hospitalization rates setting a national record on Thursday for the third day in a row, according to The COVID Tracking Project. This week, Pfizer announced a 90% efficacy rate for its investigational COVID-19 vaccine based in early data, and the FDA granted emergency use authorization (EUA) for bamlanivimab to treat mild-to-moderate COVID-19 infection.

Here’s a roundup of the latest coronavirus-related news:

AmerisourceBergen Reaches Agreement with CDC to Support Independent Retail Pharmacies’ Access to COVID-19 Vaccine​

AmerisourceBergen has reached an agreement with the CDC to include Good Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19 Vaccination.

Read more​

FDA Fast Tracks Novavax’s COVID-19 Vaccine Candidate​

The FDA has granted Fast Track Designation for Novavax’s vaccine candidate for COVID-19.

Read more​

FDA Grants EUA to Bamlanivimab for COVID-19​

The FDA granted EUA to bamlanivimab (LY-CoV555), Eli Lilly’s investigational neutralizing antibody for the treatment of mild-to-moderate COVID-19.

Read more​

Pfizer’s COVID-19 Vaccine Shows 90% Efficacy Rate in Interim Analysis​

Pfizer and BioNTech’s investigational vaccine candidate for COVID-19 was found to be more than 90% effective, according to results of an interim analysis.

Read more​

NORD Report: COVID-19 Telehealth Surge Especially Important for People With Rare Diseases​

Millions of Americans need continued access to telehealth services, especially those with rare disorders, many of which are autoimmune diseases, according to the National Organization for Rare Disorders (NORD).

Read more on Managed Healthcare Executive​